Base case and scenario analyses
| Strategy | Cost | Incremental Cost ($) | Effectiveness (QALYs) | Incremental Effectiveness | Incremental Cost-Effectiveness | ICER |
|---|---|---|---|---|---|---|
| Base case | ||||||
| CEA | $24,624 | 6.83 | 3605 | |||
| CAS | $30,731 | $6107.00 | 6.71 | −0.12 | 4580 | Dominateda |
| SAPPHIRE | ||||||
| CEA | $77,377 | $14,801.48 | 5.14 | −1.96 | 15049 | Dominateda |
| CAS | $62,576 | 7.1 | 8814 | |||
| EVA-3S | ||||||
| CEA | $22585 | 6.82 | $3312 | |||
| CAS | $30,832 | $8246.38 | 6.67 | −0.15 | $4695 | Dominateda |
| CREST | ||||||
| CEA | $22,259 | 6.89 | $3227 | |||
| CAS | $25,846 | $3587.00 | 6.63 | −0.27 | $3900 | Dominateda |
Note:—ICER indicates incremental cost-effectiveness ratio.
↵a “Dominated” means that the treatment modality was associated with more cost and less effectiveness.